Genentech Reports Annual Revenues of $9.0 Million in 1980 Vs. $3.4 Million in 1979

South San Francisco, Calif. -- February 18, 1981 -- Genentech, Inc., in its first report on operations since it went public, today reported revenues of $9.0 million, up 163 per cent from the previous year's $3.4 million.

The five year old gene-splicing company reported 1980 earnings of $236,000 or 4 cents per share. Earnings in 1979 were $116,000 or 2 cents per share.

Robert A. Swanson, President and Chief Executive Officer, noted that three products - human insulin, human growth hormone and interferon - all made by microbes developed at Genentech - are now undergoing human clinical trials. He said, "The Company expects operating results in 1981 to continue to reflect the impact of extensive investments in product research & development and clinical testing, prior to the marketing of the Company's products."

# # #

GENENTECH, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)

Year Ended December 31	1980		1979
Revenues	$	8,962,079	$	3,405,804
Net income (a)	236,291		116,336
Share earnings:
Net income	0.04		0.03

(a) Includes benefit of utilization of net operating loss carry forward

###